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1. Introduction 
1.1 Background  
Helicobacter pylori infection is one of the most common bacterial infections worldwide.1,2 
Nearly 50% of the world’s population is affected.3 Though the prevalence of this infection 
appears to be decreasing in many parts of the world, H. pylori remains an important factor 
linked to the development of peptic ulcer disease, gastric malignancy and dyspeptic 
symptoms.4 Majority of H. pylori infected persons remain asymptomatic. Approximately 10-
15% of the infected persons develop associated illnesses, 1 to 10% developing peptic ulcer 
disease, 0.1 to 3% developing gastric cancer and less than 0.01% developing gastric mucosa- 
associated lymphoid tissue (MALT) lymphoma. 
There are several lines of evidence implicating H. Pylori in the development of gastric and 
duodenal ulcers. 
1. H. Pylori is found in most patients who have peptic ulcers in absence of NSAID use. 
2. Presence of H. Pylori is a risk factor for the development of ulcer. 
3. Eradication of H. Pylori significantly reduces the recurrence of gastric and duodenal 
ulcers. 
4. Treatment of H. Pylori infection leads to more rapid and reliable ulcer healing than 
does treatment with anti-secretory therapy alone.15,21 
Early studies have estimated the rate of H. Pylori infection in patients with duodenal ulcer 
to be as high as 90% and in gastric ulcer to be as high as 70 to 90%.5,6,7,29 Despite the 
decreasing prevalence of H. Pylori infection in developed countries, it is still an important 
factor in the aetiology of non-iatrogenic peptic ulcer disease. Up to 80% of duodenal ulcers 
and 70% of gastric ulcers are associated with H. Pylori infection. Several studies have shown 
that a pre- existing H. Pylori infection increases the risk for developing peptic ulcer 
disease.8,9,10,11 In one study, 11% of patients with H. Pylori gastritis developed peptic ulcer 
disease compared to 1% of persons without gastritis.10 Eradication of H. Pylori infection 
significantly reduces the recurrence of gastric and duodenal ulcers.12,13,14,21 One study 
reviewed the relationship between H. Pylori eradication and reduced recurrence of 
duodenal and gastric ulcers. Ulcer recurrence was significantly less common among H. 
Pylori cured patients versus non-cured patients (6% versus 67% for patients with duodenal 
ulcers; 4% versus 59% for patients with gastric ulcers).12  
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H. Pylori has also been linked to the development of idiopathic thrombocytopenic purpura, 
ischemic heart disease and cerebrovascular accident. However, if confounding factors are 
taken into consideration, the strength of these associations is reduced.16, 17, 221 
2. Bacteriology 
Helicobacter pylori is a unipolar, multiflagellate, spiral shaped, microaerophilic, gram 
negative bacterium.18 The bacterium was first isolated by Marshall and Warren in 1983 from 
gastroscopy biopsy specimens, which they described as a new species related to the genus 
Campylobacter.18 The new genus Helicobacter was first published in October 1989. At least 
22 species are now included in this genus, the majority of which colonise mammalian 
stomachs or intestines. 
Helicobacter pylori is a slow growing bacterium. It can be cultured on non-selective agar 
media, such as blood agar, chocolate agar or on selective agar media, such as Skirrows 
media incubated in a humidified, micro-aerobic (5% oxygen) atmosphere at 35 to 37 degree 
centigrade for three to seven days.19 Small, translucent circular colonies form and organisms 
are identified as Helicobacter pylori based on typical cellular morphology and positive 
results for oxidase, catalase and urease tests. 
Under stress and nutritional deprivation, H. Pylori undergoes a morphological 
transformation from spiral bacilli to inactive coccoids.19 H. Pylori cell wall enzyme Ami A, a 
peptidoglycan hydrolase, is involved in this morphologic transition.20 Coccoid forms may be 
indicative of a dormant state. Coccoid forms may enable the organism to survive outside the 
human host in faeces or in water. 
3. Epidemiology 
Helicobacter pylori is one of the most common bacterial infections worldwide. At least 50% 
of the world’s population is infected. The prevalence of H. Pylori infection in a community 
is related to three factors: 1. Rate of acquisition of infection, i.e. the incidence 2. the rate of 
loss of the infection 3. the prolonged prevalence of the bacterium in the gastro-duodenal 
mucosa between infection and eradication. [Prevalence is directly related to incidence and 
duration of illness].2 Acute H. Pylori infection invariably passes undetected. Thus, the 
incidence of infection is determined indirectly from epidemiological studies. The incidence 
of H. Pylori infection is estimated to be approximately 0.5% per year in adults of developed 
countries. This incidence has been decreasing over time. However, the incidence of H. Pylori 
infection continues to be high in developing countries (3% to 10% per year).25 
The infection is usually acquired in the first few years of life. Once acquired, infection 
persists indefinitely unless treated. In developing countries, the majority of children become 
infected during childhood and chronic infection continues during adulthood.2,26 By age 1 
year, approximately 20% are infected and by age 10 years, 50% are infected.26 The 
prevalence of H. Pylori infection may be as high as 80% in adults.30,31 However, in 
developed countries, such as, the United States, evidence of infection is rare before age 10, 
but increases to 10% between 18 and 30 years of age and to 50% in those older than age 60.2 
The higher prevalence in older age groups is thought to reflect a cohort effect related to 
poorer living conditions of children in previous decades. Within any age group, H. Pylori 
infection is more common in non-Hispanic blacks and Hispanics compared to the white 
population, which may be related to socioeconomic factors.27, 28 
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Important risk factors for H. Pylori infection are socioeconomic status and living conditions 
during childhood. Lower socioeconomic status and poor living conditions during childhood 
have been associated with higher risk of acquiring H. Pylori infection.38,39,40,41 There may 
also be genetic susceptibility to H. Pylori infection.42,43 Twin studies support hereditary 
susceptibility to infection, but this has not been proven. Individuals of certain ethnic groups 
including Hispanics and blacks have a higher rate of infection than Caucasians, which are 
not entirely explained by differences in socioeconomic status.44 
4. Helicobacter pylori transmission 
The mode of transmission of H. Pylori infection is poorly known.1,45 Various modes of 
transmission have been suggested, such as person-to-person, water-borne, food-borne and 
zoonotic transmission.45,46,47,48,49,50,51,52,53,54 The transmission of H. Pylori seems to be direct 
from person-to-person via faecal-oral or oral-oral routes.45,46 Certain epidemiological studies 
have suggested water-borne and food-borne transmissions.51,52,53,54 Zoonotic transmission 
has also been suggested based on isolation of H. Pylori from primates, domestic cats and 
sheep. 47,48,49 
Person-to person transmission is supported by the increased prevalence of infection among 
family members of patients with H. Pylori and among institutionalized patients. Isolation of 
genetically identical strains of H. Pylori from infected members of the same family and in 
patients in a chronic care facility further support this hypothesis.32,33,34,35,36,37 Faecal-oral 
transmission is a possibility as H. Pylori has been cultured from faeces54,55 and the organism 
seems to survive in water in non-culturable forms50,51,52 (detected by PCR techniques). There 
is some indirect, but scarce evidence for oral-oral transmission.45 H. Pylori has been 
identified in dental plaques56, but it is unknown if this location can serve as a reservoir. 
Gastro-oral route of transmission through vomitus has also been suggested based on 
presence of bacteria in gastric secretions.57,58 
Studies employing microbiological techniques have demonstrated that Helicobacter pylori is 
present in water and other environmental samples all over the world. Epidemiological 
studies have shown that water source and exposures related to water supply, including 
factors related to sewage disposal and exposure to animals, are risk factors for infection.51 
Children who swim in rivers, streams, pools, drink stream water or consume raw vegetables 
are more likely to be infected.53 H. Pylori has also been detected in various food samples. So 
it has been hypothesised that food or water may be a reservoir in H. Pylori transmission. 
Iatrogenic transmission has also been documented after the use of inadequately disinfected 
endoscopes and endoscopic accessories.58 
5. Patho-physiology 
5.1 Patho-physiology of gastric ulcers 
Up to 70% of gastric ulcers are associated with H. Pylori infection. Three types of gastric 
ulcers have been described. Type I ulcers occur in the body of the stomach and are not 
related to other gastro-duodenal disease. Type II ulcers also occur in the body of the 
stomach and are associated with a duodenal ulcer scar or active ulcer. Type III ulcers occur 
in the immediate pre-pyloric area. Type II and III ulcers are associated with higher levels of 
gastric acid secretion as seen in patients with duodenal ulcers, but type I ulcers tend to be 
associated with normal or low levels of gastric acid secretion. Role of H. Pylori in these 
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different types of gastric ulcer is not known. Gastric acid secretion may not be the most 
important factor in the development of gastric ulcers as gastric ulcers have been seen in the 
presence of achlorhydria.59 It has also been observed that basal and stimulated gastric acid 
secretion is within normal limits in groups of patients with gastric ulcers 
5.2 Patho-physiology of duodenal ulcers 
The mechanism by which Helicobacter pylori predisposes to duodenal ulcer is unclear. The 
pathogenesis of duodenal ulcer appears to be multi-factorial, involving an imbalance 
between “damaging” (e.g. acid, pepsin) and “protecting” (e.g. mucus, mucosal barrier, 
bicarbonate production, blood flow, cellular regeneration) factors.60The bacterium seems to 
affect different aspects of gastric and intestinal mucosal physiology that may contribute to 
development of ulcer disease. Disturbances in gastric acid secretion, gastric metaplasia, host 
inflammatory and immune response and down-regulation of various mucosal defence 
factors may contribute to ulcer formation. Various bacterial, host and environmental factors 
may also have a role in the pathogenesis of duodenal ulcer. 
5.2.1 Disturbances in gastric acid secretion 
Gastric acid secretion is elevated in patients with duodenal ulcers.61,70 Helicobacter pylori 
infection can alter acid secretion in both directions. Acid secretion decreases temporarily 
during acute infection and may dwindle later if H. Pylori causes gastric atrophy.63 In 
patients with duodenal ulcers, H. Pylori produces inflammation of non-acid secreting antral 
region of the stomach, whereas the more proximal acid-secreting fundic mucosa is relatively 
spared.70,71 This may explain the increased gastric acid secretion in patients with duodenal 
ulcers. When compared to H. Pylori negative subjects, patients with duodenal ulcers have 
elevated basal acid output, peak acid output, fasting and meal-stimulated gastrin 
concentrations.61,62,70 
H. Pylori infection is thought to change the physiological control of acid secretion. H. Pylori 
infection has been found to decrease the local expression of the inhibitory peptide 
somatostatin63 and to increase the release of the acid-stimulating hormone, gastrin.62,70 
Hypergastrinemia, in addition to decreased inhibitory somatostatin, may be responsible for 
the increased gastric acid secretion. Hypergastrinemia may result from a decrease in the 
inhibitory peptide somatostatin.64 Bacterial factors that inhibit somatostatin release have not 
been recognised, although TNF-alpha induced by H. Pylori infection may play a role in 
inhibiting somatostatin release.65 In patients with H. Pylori infected duodenal ulcers, there is 
an exaggerate response to stimulation by gastrin.61,70,71 This may be due to increased parietal 
cell mass in patients with duodenal ulcers60,66,71 (Duodenal ulcer patients have 
approximately twice the normal parietal cell mass). But it is unclear whether or not this is 
due to H. Pylori infection.67 Increased parietal cell mass may be due to trophic effects of 
hypergastrinemia over time or it may be related to host factors. 
5.2.2 Gastric metaplasia 
Elevated gastric acid secretion increases the duodenal acid load, which damages the 
duodenal mucosa, causing ulceration and gastric metaplasia. Gastric metaplasia occurs in 
the duodenum in response to acidic PH (when PH is less than 2.5).68 Metaplastic gastric 
epithelium allows H. Pylori to colonise the duodenal mucosa, where it produces an acute 
inflammatory response. Colonization of these areas of gastric metaplasia by H. Pylori may 
significantly increase the risk of ulceration.69 
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However, gastric metaplasia is found in most, but not all patients with duodenal 
ulcers.72,73,74 Gastric metaplasia can also be commonly found in the duodenum of healthy 
persons.73,74,75 Studies have found a similar prevalence of gastric metaplasia among patients 
with duodenal ulcers and non ulcer dyspepsia.76 Therefore, the role of gastric metaplasia in 
the pathogenesis of duodenal ulcer disease is unclear. 
5.2.3 Host immune and inflammatory response 
Host immune system responds to H. Pylori infection by production of inflammatory 
cytokines, such as interleukin(IL)-1, IL-6, tumor necrosis factor alpha, IL-8. These 
inflammatory cytokines may have a role in the development of duodenal ulcer. 
5.2.4 Down-regulation of mucosal defence factors 
i. Mucus- Mucus is a protective coat overlying the intestinal mucosa. Helicobacter pylori 
produces proteolytic enzymes that degrade this mucus layer, thus exposing the 
underlying mucosa to damaging effects of acid.77 
ii. Bicarbonate- Most patients with duodenal ulcers have impaired proximal duodenal 
mucosal bicarbonate secretion. Impaired bicarbonate secretion in patients with 
duodenal ulcers could be caused by a cellular and/or physiological regulatory 
transport defect possibly related to H. Pylori infection as eradication of the infection 
normalises proximal mucosal bicarbonate secretion.78 
iii. Cellular regeneration- Epidermal growth factor (EGF) and transforming growth factor-
alpha(TGF-alpha) are potent gastric acid inhibitors and stimuli of mucosal growth and 
protection. H. Pylori may contribute to ulcerogenesis by affecting these factors for 
cellular regeneration as eradication of H. Pylori infection has shown to increase mucosal 
content and expression of TGF-alpha, EGF and EGF receptor (EGFr).79 
iv. Blood flow- Thrombotic occlusion of surface capillaries is promoted by a bacterial 
platelet activating factor. Circulating platelet aggregates and activated platelets were 
detected in patients with H. Pylori infection. Platelet activation and aggregation may 
contribute to microvascular dysfunction.84 This may play a role in producing mucosal 
damage and ulcer. 
5.2.5 Other contributing factors 
i. Bacterial factors- Various bacterial factors, such as the bacterial strain may play role in 
the pathogenesis of duodenal ulcer. For example, Strains with the cytotoxin-associated 
gene A(cag A) are associated with duodenal ulcer. Approximately 95% of patients with 
duodenal ulcers have cag A+ strains compared to 65% of infected patients without 
ulcers.80 
ii. A specific Helicobacter pylori gene, duodenal ulcer promoting gene (dupA) is 
associated with an increased risk of duodenal ulcer. One study found that dup A was 
present in 42% of patients with duodenal ulcer versus 21% of patients with gastritis 
(adjusted odds ratio[OR]=3.1, 95% confidence interval; CI-1.7-5.7).81 Its presence was 
also associated with more intense antral neutrophil infiltration and interleukin-8 levels 
and was a marker for protection against gastric atrophy, intestinal metaplasia, and 
gastric cancer.81,82 
iii. Host factors- Host factors may be important in the development of duodenal ulcer. For 
example, patients with Helicobacter pylori who develop duodenal ulcer have higher 
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parietal cell mass or sensitivity to gastrin than Helicobacter pylori infected healthy 
persons.60,66,71 
iv. Environmental factors, such as NSAID use and smoking may also increase the risk of 
duodenal ulcer in patients with Helicobacter pylori infection.83 
5.3 Pathogenesis of H. Pylori-induced peptic ulcer disease 
H. pylori causes three major gastric morphologic changes.87 The extent and distribution of 
H. Pylori-induced gastritis ultimately determine the clinical outcome. The commonest 
morphologic change is the “simple or benign gastritis”, characterized by mild pangastritis 
with little disruption of gastric acid secretion. This form of gastritis is commonly seen in 
asymptomatic people with no serious gastrointestinal disease. Up to 15 % of infected 
subjects develop an antral-predominant gastritis with relative sparing of the acid producing 
corpus mucosa. Subjects with antral-predominant gastritis have high antral inflammatory 
scores, high gastrin levels, relatively healthy corpus mucosa and very high acid output.70 
These abnormalities lead to the development of peptic ulcers, particularly duodenal and a 
large proportion of pre-pyloric ulcers. Up to 1% of infected subjects develop a corpus 
predominant pattern of gastritis, gastric atrophy and hypo- or achlorhydria.85 These 
abnormalities develop as a direct result of the chronic inflammation induced by the infection 
and increase the risk of gastric cancer. 
It is believed that the complex interplay between the host and the bacterium determines the 
disease outcome. Various bacterial factors have been described which aid in the colonisation 
of the gastric mucosa and subsequent modulation of the host’s immune response. Studies 
have investigated the impact of these bacterial factors on inflammation and disease 
outcome. Role of bacterial factors for disease outcome remains limited, with most “virulent” 
strains being found in asymptomatic subjects.86 Therefore, the variation in the host’s 
inflammatory and immune response to infection may play a key role in determining the 
disease outcome. Nonetheless, the bacterium is required to initiate the host’s response. 
5.3.1 Bacterial factors 
i. Colonisation/ Bacterial attachment 
H. pylori is very sensitive to acid and it dies rapidly in the acidic PH found in the gastric 
lumen. Bacterial motility, urease and its ability to adhere to gastric epithelium are the factors 
that allow it to survive in the acidic environment.87 
Various changes are observed in H. Pylori expression of genes following exposure to low 
PH. There is an increase in the expression of genes encoding proteins involved in the 
motility apparatus as well as genes encoding urease and proteins associated with the 
optimal function of the urease.88 These observations suggest that the bacterial genes are 
turned on in the gastric mucosa. 
H. pylori is capable of swimming freely within the mucus gel by utilising its polar flagella. It 
seems that the bacterium is able to sense and respond to PH gradients by swimming away 
from the acidic PH.89 This allows the bacterium to swim away from the acidic PH in the 
gastric lumen to the close proximity of gastric epithelium, where the PH is near normal. In 
this environment, it enjoys the same cytoprotective mechanism as the gastric epithelium. 
Other remarkable feature of H. Pylori is its ability to produce large amounts of cytosolic and 
cell surface associated urease. The urease produced by H. Pylori functions optimally at 2 
different PH values, 7.2 and 3.91Cell-surface associated urease hydrolyses gastric luminal 
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urea to ammonia that helps neutralise gastric acid and form a protective cloud around the 
bacterium.92 Within H. Pylori’s urease gene cluster, there is a specific gene, Ure I, which 
encodes for a PH dependent urea channel.22 The urea channel allows movement of urea 
from gastric lumen into the cytoplasm. The metabolism of urea by the cytosolic urease 
generates ammonia ions, which buffer hydrogen ions as they reach the cytoplasm of the 
organism.93,94 
H. pylori infects gastric type epithelium to which it adheres closely. Adherence of the 
bacterium to the gastric epithelium is an important virulence factor and is necessary for the 
induction of pro-inflammatory responses. Adhesion to gastric epithelium may be beneficial 
to the bacterium in many ways. It may protect the bacterium against the mechanical 
clearance. Adhesion may promote invasion and persistence. The bacterium may use the cell 
surface as a site of replication. Increased inflammation and cellular damage caused by 
adhesion may release nutrients for H. Pylori. Adhesion also plays a major role in the 
delivery of toxins such as, Cag A and Vac A to host epithelial cell.87 
Approximately 20% of H. Pylori in the stomach are found attached to the surfaces of mucus 
epithelial cells.90 Adhesion is mediated by specific interactions between bacterial adhesin(s) 
and host receptor(s).23,24 Over 30 genes in H. Pylori genomes are dedicated to the expression 
of outer membrane proteins (OMPs). Several of these OMPs have been classified as 
adhesins. Best described adhesins are BabA, Oip A and SabA. The leb-binding adhesin, 
BabA mediates binding to fucosylated Lewis b(Leb b) histo-blood group antigen on gastric 
epithelial cell.95 Epidemiological studies also provide evidence in support of interaction 
between Leb and Bab A. For example, Strains of H. Pylori with BabA2 genotype are 
associated with inflammation, duodenal ulcer and gastric cancer.96,97 Outer membrane 
protein (Oip A) coded by HPO638 gene may act as adhesins as well as promote 
inflammation by inducing IL-8 production.98 However, their receptors have not yet been 
characterized. Sialic acid-binding adhesin (SabA) mediates binding to sialyl-dimeric-Lewix 
X glycosphingolipid in gastric epithelial cell.99 Many strains of H. Pylori express a 
vacuolating cytotoxin Vac A, which may serve as a ligand for bacterial attachment. 
Although the majority of the Vac A is secreted, some may remain on the surface of the 
bacteria and serve as a ligand for bacterial attachment to epithelial cells, via an interaction 
with protein tyrosine phosphatases.100 The Alp A and Alp B proteins have also been 
described as as adhesins in vitro.101 However, there is a marked heterogeneity in H. Pylori 
adhesion system.102 No individual adhesin is necessary for attachment to the gastric mucosa. 
Expression of adhesins is diverse between strains and variable within a single strain over 
time and these mechanisms of variability and adaptation are controlled at the genetic  
level by on/off switching of adhesin gene expression, gene inactivation or 
recombination.87,102,103,104,105 
Le antigens expressed by host cells may serve as the major receptor for bacterial 
binding.106,107 Bab A mediates binding to Leb receptor on host cell. However, there may be 
other host molecules besides Le antigens that can bind H. Pylori as it has been seen that the 
binding of H. Pylori to epithelial cells freshly isolated from human gastric biopsy specimens 
is unaffected by the expression of Le antigen108 and individuals who do not express Leb can 
clearly be infected with H. Pylori.109 One such host molecule may be class II major 
histocompatibility (MHC) molecule expressed on the surface of gastric epithelial cell.110 H. 
Pylori can bind to class II MHC molecules on the surface of gastric epithelial cells and 
induce apoptosis.111 A family of pathogen-associated molecular pattern receptors, the Toll-
like receptors(TLRs) have also been examined for their role in binding of H. Pylori to the 
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host epithelial cells. 11 TLRs have been described.86 Each one appears to have a different 
specificity for various bacterial molecules.112 These receptors may bind bacterial products 
and thereby, enhance both bacterial binding and signalling. For example, TLR5 binds 
bacterial flagellins113, TLR4 binds bacterial lipopolysaccharide(LPS).114,115 The gastric trefoil 
protein TFF1, predominantly expressed in the gastric mucosa and the gastric mucus may 
serve as another receptor for H. Pylori.116 A host cell glycosylphosphatidylinositol( GPI)-
anchored glycoprotein, DAF has also been described as a potential receptor for binding H. 
Pylori.117 
ii. Virulence factors 
H. pylori induced gastritis and damage to the gastric mucosa is probably secondary to 
immune recognition of the bacteria and damage from various bacterial products.87 Various 
bacterial products have been described as “toxins” based on biological activity. 
Vac A 
Many strains of H. Pylori express a pore forming cytotoxin, Vac A.118 Vac A has been shown 
to cause cell injury in vitro and gastric tissue damage in vivo.23,120,121 However for Vac A to 
cause cell damage, it must be secreted from the bacteria and delivered in an active form to 
host cell membranes where it assembles into pores that allow the leakage of chloride ions.122 
The Vac A gene shows a considerable genetic diversity. The activities of different alleles of 
the toxin vary in their toxicity. For example, strains harbouring s1 types of Vac A are highly 
associated with ulcers and gastric cancer.123 M1 types of Vac A are also associated with 
ulcers.123 Although the majority of Vac A is secreted, some remain associated with the 
bacterial cell surface. The Vac A molecules that remain on the surface of the bacteria are 
functional and delivered to host cells by direct contact between adhered bacteria and the 
host cell membrane.124 As described earlier, Vac A on the surface of the bacteria may also 
serve as a ligand for bacterial attachment via an interaction with protein tyrosine 
phosphatases.  
Several toxigenic properties of Vac A have been described that may contribute to the 
development of the disease.125,126 Vac A may lead to vacuolation of epithelial cells, probably 
through its effect on endosomal maturation.87 Vac A also induces apoptosis of host cells, 
probably through the activation of pro-apoptotic signalling molecules127 and pore formation 
in mitochondrial membranes.128 Vac A may disrupt the barrier function of tight junctions, 
leading to the leakage of ions and small molecules, such as iron, sugars and amino acids.129 
Vac A was also found to be a powerful inhibitor of T-cell activation in vitro.130 
Cag A and the cag Pathogenicity island (Cag PAI) 
Cag A is an important virulence factor associated with H. Pylori. It was initially thought to 
be the most important virulence factor as patients with antibodies against this protein 
showed higher rates of peptic ulcer disease119 and gastric cancer. 131,132,133 Cag A positive 
strains have also been associated with increased inflammation134, cell proliferation135 and 
gastric metaplasia.136 However, 30 to 60% of patients infected with CagA + strains do not 
develop any significant disease.80 Therefore, Cag A may not be the most important virulence 
factor. 
Cag A is a 128 to 140 kd protein, that can activate a number of signalling mechanisms and 
thus, affect the structure, differentiation and behaviour of epithelial cells.87 Cag A is 
translocated into the host cell by the type 4 secretion system( TFSS). Genes within the cag 
pathogenicity island(PAI) encode proteins for the type 4 secretion apparatus(TFSS), also 
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referred to as Cag E.125,137 These genes are co-transcribed and are genetically linked to Cag 
A.120 TFSS allows bacterial macromolecules, such as Cag A, peptidoglycan to be translocated 
into the host cell.125,137 The intact cag PAI of H. Pylori plays an important role in the 
pathogenesis of gastritis.125,137,138 For example, Mutations of H. Pylori cag region were 
associated with decreased gastric mucosal inflammation in vivo and reduced activation of 
IL-8 or apoptosis in vitro.139 It is believed that cag PAI results in the activation of nuclear 
factor(NF-kb) and AP-1, which in turn, regulate the expression of a wide variety of pro-
inflammatory cytokines.140,141 Cag PAI may collaborate with other bacterial factors, such as 
Oip A to enhance IL-8 production.142 Bacterial peptidoglycan may also leak into the cell 
through the TFSS, resulting in the activation of Nod-1 mediated inflammatory response.143 
Once inside the host cell, Cag A is tyrosine phosphorylated by host Src kinases.144 Src 
kinases are normally involved in controlling basic cytoskeletal process, cell proliferation and 
differentiation. After its tyrosine phosphorylation, it interacts with a number of host 
proteins, triggering growth receptor-like signalling. Through these signal transduction 
events, Cag A affects the proliferative activities, adhesion and cytoskeletal organisation of 
epithelial cells.87,145,146,147 Cag A also perturbs cell cycle control.148 Cag A may also have a 
phosphorylation independent effect on gene transcription.149 Independently of tyrosine 
phosphorylation, Cag A can form complexes with several junction proteins such as Zo-1, 
JAM and E-cadherin and can perturb the assembly and function of both the tight junction 
and the adherens junctions.150,151 Phenotypically, this leads to the deregulation of epithelial 
cell-cell adhesion and loss of epithelial polarity.152 Cag A, independent of cag TFSS, can 
activate the nuclear factor, NF-kb leading to activation of pro-inflammatory signal and IL-8 
secretion.140,141 Cag A may also induce DNA damage and apoptosis of gastric epithelial cells 
via oxidative stress.171 
Other virulence factors 
Most persons infected with H. Pylori strains that produce Vac A and possess Cag A 
genotype nonetheless remain asymptomatic, suggesting that additional virulence factors are 
important in virulence. Several other H. Pylori virulence factors, such as ice A, Bab A2, Oip 
A have been described.153,154,155,156,157 For example, “induced by contact with epithelium” ice 
A has been linked to peptic ulcers and increased mucosal concentrations of IL-8.153,154,155 H. 
Pylori strains with “blood group antigen binding adhesin” Bab A2 genotype are associated 
with inflammation, duodenal ulcer and gastric cancer156. Oip A has been associated with 
duodenal ulcers.157 However, the importance of these virulence factors in the life of H. 
Pylori is poorly understood. 
iii. Mechanism of persistence 
In order to colonise the human stomach, H. Pylori must overcome the physical and chemical 
barriers as well as innate and adaptive immune responses that are triggered in the stomach 
by its presence.87 H. Pylori urease functions mainly as a protective buffering enzyme against 
gastric acidity. Several bacterial factors including catalase and urease antagonise innate host 
immune responses.158 H. Pylori may decrease the expression of the antibacterial molecule 
secretory leukocyte protease inhibitor.159 H. Pylori produces an enzyme, arginase that 
inhibits nitric oxide production and may favour bacterial survival.160 Virulent strains of H. 
Pylori may alter mucus production161 and phagocytosis.162 A number of H. Pylori factors 
may actually contribute to reduce inflammation or recognition by the immune system. 
Molecular mimicry may be an important mechanism employed by the bacterium to evade 
recognition by the host immune system. For example, H. Pylori flagellar proteins have 
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evolved to avoid being recognised by toll-like receptors.163 H. Pylori lipopolysaccharides 
mimic host molecules such as Lewis antigens.164 H. Pylori virulence factors elicit both pro-
inflammatory cytokines such as INF-gamma, TNF-alpha and anti-inflammatory cytokines, 
such as IL-4, !L-10 and transforming growth factor-beta. These anti-inflammatory cytokines 
may impair immune responses and may favour persistence.86 However, these anti-
inflammatory cytokines, IL-4, IL-10 and TGF-b are not expressed to the same levels as pro-
inflammatory cytokines.165,166,167,182 Hence, it has been hypothesized that H. Pylori induces a 
robust, but specific form of chronic inflammation that is ineffective in clearing the infection 
while avoiding forms of inflammation that would eliminate it.87 This may be due to 
inappropriate T-cell responses or a lack of coordination in T-cell responses required for 
immunity.86 A number of host polymorphisms may also lead to variations in the immune 
response.87 
5.3.2 Role of host response in H. Pylori induced disease 
As described earlier, the host response to H. Pylori infection is an important component in 
the pathogenesis of gastro-duodenal disease. H. Pylori induce chronic inflammation in the 
gastric mucosa, mediated by an array of pro- and anti-inflammatory cytokines. 
Heterogeneity in the regions of genome that control the magnitude of inflammation is 
thought to determine an individual’s ultimate clinical outcome. For example, genetic 
polymorphisms in the regions controlling IL-1 beta were associated with an increased 
incidence of hypochlorhydria, gastric cancer and decreased occurrence of duodenal 
ulcer.168,169 Il-1 beta has a profound pro-inflammatory effect and it is also a powerful acid 
inhibitor.170 The pro-inflammatory genotypes of TNF-alpha, IL-8 and IL-10 were associated 
with the development of gastric cancer.168 
i. Epithelial cell response to H. Pylori infection 
The epithelial cell response to H. Pylori infection is determined by several variables: 
bacterial virulence factors, the signalling linked to specific receptors that recognise the 
bacterial components and the local effects of hormones, neurotransmitters, 
immune/inflammatory cytokines and stromal factors.86 These responses include changes in 
epithelial cell morphology175, increased epithelial cell proliferation176, increased rates of 
epithelial cell death via apoptosis177, disruption of the tight junctional complexes150, the 
production of inflammatory cytokines137 and induction of numerous genes, most 
importantly genes involved in the regulation of the immune/inflammatory responses, 
epithelial cell turn over including apoptosis and proliferation and those affecting 
physiological properties in the stomach.178,179,180,181 The expression of these genes in 
epithelial cells is modulated by transcription factors that are controlled by a series of 
signalling mechanisms. For example, nuclear factor kb(NF-kb) and AP-1 regulate the 
expression of pro-inflammatory cytokines and cellular adhesion molecules in response to 
infection.182,183 These transcription factors are controlled by several signalling mechanisms 
including mitogen-activated protein kinases(MAPKs).138,184 The MAPK cascades regulate 
several cell functions including proliferation, inflammatory responses and cell survival. ERK 
and P38 MAPK pathways regulate IL-8 production in gastric epithelial cells.185,186 ERK and 
P38 also regulate the expression of other inflammatory response genes. Specific bacterial 
products as described earlier activate different transcription factors, which collaborate to 
enhance IL-8 production.86 Interleukin-8 and related peptides in chemokine family secreted 
by gastric epithelial cells recruit and activate neutrophils and macrophages. 
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ii. Host responses in the lamina propria  
Although H. Pylori resides predominantly in the gastric lumen, it induces a robust 
inflammatory and immune response. The magnitude of the host inflammatory response 
cannot be explained solely based upon the host epithelial cell responses to the bacterium. 
Significant amounts of bacterial product may leak around epithelial cells and reach the 
lamina propria, where it can activate phagocytes, including macrophages and neutrophils.86 
Disruption of epithelial tight junctions may enhance bacterial antigen delivery to the lamina 
propria. Several studies have demonstrated the ability of H. Pylori to invade gastric 
epithelial cells in vitro and in vivo.172,173 Transmission electron microscopy and immunogold 
detection have shown H. Pylori to be in direct contact with immune cells of the lamina 
propria in the majority of cases of gastritis.174 Engulfment of H. Pylori infected epithelial 
cells by phagocytes may be one of the mechanisms by which H. Pylori can activate the host 
immune response.187 
Several bacterial products have been shown to trigger immune response within the lamina 
propria. A broad array of cytokines is released in the lamina propria in response to intact 
bacteria or bacterial factors. One such bacterial factor is H. Pylori neutrophil-activating 
protein, a 150 kilodalton protein, which promotes neutrophil adhesion to endothelial cells 
and stimulates chemotaxis of monocytes and neutrophils.188 Bacterial urease can induce he 
production of IL-6 and TNF-alpha by macrophages.189 Heat shock protein 60 induces the 
production of IL-6.190 Intact bacteria can induce the production of chemokines that recruit T-
cells191 as well as IL-12192 and IL-18193, that favour the selection of Th1 cell. Increased IL-1, 
IL-6, IL-8 and TNF-alpha in response to H. Pylori infection recruit and activate monocytes 
and neutrophils. Release of neutrophil mediators may in turn, disrupt epithelial cells and 
contribute to ulcer formation. 
iii. Gastric T-cell responses 
Bacterial activation of epithelial cells, monocytes, macrophages and neutrophils leads to a T-
helper cell type of adaptive response.194,195 Different T-helper cell subsets emerge in 
response to infection with characteristic cytokine production. In H. Pylori infection, T-cell 
response is predominantly of T-helper cell 1(Th1) type.138,196 Th1 cells promote cell-mediated 
immune responses, mainly through the production of INF-gamma and TNF-alpha while 
Th2 cells promote humoral immunity through the production of cytokines, such as IL-4, IL-
5, IL-10 and IL-13. Previously, it was thought that the gastric mucosa is pre-conditioned to 
favour Th1 cell development.165,192,197 One possible hypothesis is that H. Pylori selectively 
blocks Th2 development by interfering with STAT6 activation by IL-4.198 IL-12 and IL-18 
induced in response to infection may positively select for the Th1 response.86 Activated Th1 
cells produce INF-gamma and TNF-alpha which increase the expression of many pro-
inflammatory genes in the epithelium including IL-8.182 These cytokines also enhance 
bacterial binding110 and may contribute to increased bacterial load.199 Th1 cells may induce 
epithelial cell death through Fas-Fas L interactions.200 In summary, Th1 activation may 
contribute to more severe inflammation and mucosal damage. However, Th1 type of T-cell 
response is a type of cell-mediated immunity against the control of intracellular 
pathogens.196 It is unlikely to be effective against H. Pylori which is largely an extracellular 
pathogen. Hence, Th1 cell activation may produce inflammation, but not effective one which 
would clear the infection. In addition to Th1 cells, a subset of anti-inflammatory T-cells may 
be activated by H. Pylori infection. These cells may impair excessive inflammation which 
would otherwise lead to the clearance of the organism.86 
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iv. Gastric B-cell responses 
Gastric T-cells can modulate B-cell responses, leading to the production of specific 
antibodies to a variety of H. Pylori antigens. During infection with H. Pylori, Ig G, Ig A and 
Ig M types of antibodies can be detected.201,202 The role of these antibodies in the disease is 
poorly understood. Ig G class of antibody can activate complement and may contribute to 
immune-complex mediated inflammation.203 In addition to producing antigen-specific 
antibodies, B-cells have also been shown to produce auto-reactive antibodies, that may be 
pathogenic.204,205 
6. Indications for H. pylori testing 
H. pylori is a common worldwide infection. The vast majority of patients with H. Pylori 
infection do not develop clinically significant gastroduodenal disease. Therefore, routine 
testing for H. Pylori is not recommended. When to test a patient for H. Pylori infection is an 
important question for a clinician. Guidelines from the American college of 
Gastroenterology [ACG] and the European Helicobacter study group [EHSG] have been 
published to assist clinicians in making this decision. 
ACG recommendations206 
Testing for H. Pylori should only be performed if the clinician plans to offer treatment for 
positive results. 
Testing is indicated in patients with 
1. Active peptic ulcer disease( gastric or duodenal ulcer) 
2. Confirmed history of peptic ulcer disease( not previously treated for H. Pylori) 
3. Gastric MALT lymphoma( low grade) 
4. After endoscopic resection of early gastric cancer 
5. Uninvestigated dyspepsia( depending upon H. Pylori prevalence) 
The test-and-treat strategy for H. Pylori infection is a proven management strategy for 
patients with uninvestigated dyspepsia who are under the age of 55 yr and have no “alarm 
features” ( bleeding, anaemia, early satiety, unexplained weight loss, progressive dysphagia, 
odynophagia, recurrent vomiting, family history of GI cancer, previous esophagogastric 
malignancy) 
Deciding which test to use in which situation relies heavily upon whether a patient requires 
evaluation with upper endoscopy and an understanding of the strengths, weaknesses, and 
costs of the individual test. 
EHSG recommendations207 
Testing is indicated in patients with 
1. Gastroduodenal diseases such as peptic ulcer disease and low grade gastric MALT 
lymphoma 
2. Atrophic gastritis 
3. First degree relatives of patients with gastric cancer 
4. Unexplained iron deficiency anaemia 
5. Chronic Idiopathic thrombocytopenic purpura (ITP) 
The test-and-treat strategy using a non-invasive test is recommended in adult patients with 
persistent dyspepsia under the age of 45 and no “alarm symptoms”. 
Testing is not recommended in GORD. However, testing should be considered in patients 
on long-term maintenance therapy with PPIs. 
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Testing should be considered in patients who are naive NSIADs users. 
Testing should be considered in patients who are long-term aspirin users who bleed. 
Children with recurrent abdominal pain, who have a positive family history of peptic ulcer 
and gastric cancer should be tested for H. Pylori after exclusion of other causes. 
Duodenal and gastric ulcer 
Testing for H. Pylori is indicated in patients with confirmed gastric or duodenal ulcers. As 
described earlier, H. Pylori has been established as a major risk factor for both duodenal and 
gastric ulcers. H. Pylori eradication has also shown to reduce the recurrence of peptic ulcer 
disease. Therefore, both ACG and EHSG recommend testing patients with peptic ulcer 
disease for H. Pylori. 
Gastroduodenal bleeding 
A meta-analysis performed by Sharma et al showed that H. Pylori treatment decreased 
recurrent ulcer bleeding by 17% and 4% compared with ulcer healing treatment alone ( 
bismuth, ranitidine or omeprazole) or ulcer healing treatment followed by maintenance 
therapy respectively.208 Another study performed in Taiwanese patients with a history of 
ulcer bleeding showed that maintenance acid suppression was not routinely necessary to 
prevent ulcer recurrence after successful H. Pylori cure and ulcer healing.209 Therefore, 
patients with a bleeding duodenal or gastric ulcer should be treated for H. Pylori. 
Uninvestigated dyspepsia 
The Cochrane Systematic review confirmed that there is a small benefit of eradicating H. 
Pylori in patients with non-ulcer dyspepsia.210 Eradication of H. Pylori may also reduce 
the incidence of peptic ulcer in patients with ulcer-like functional dyspepsia.211 Therefore, 
the test-and-treat strategy is recommended in patients with uninvestigated dyspepsia 
who are under the age of 55 yrs or 45 yrs (depending upon the specific set of guidelines) 
and have no “alarm features”. However, this strategy has been criticised. In a placebo-
controlled trial of empirical treatment involving 294 patients with uninvestigated 
dyspepsia and a positive H. Pylori breath test, the 1-year rate of symptom resolution was 
50% in those receiving H. Pylori eradication therapy, as compared with 36% of those 
receiving placebo (p=0.02)212; 7 patients would need to receive eradication therapy for 1 
patient to have a benefit. This suggests that most patients treated with the test-and-treat 
strategy would incur the inconvenience, costs and potential side-effects of therapy 
without a benefit. 
Long-term maintenance therapy with PPIs 
EHSG suggests H. Pylori testing in patients on long-term maintenance therapy with PPIs. 
Patients who are infected with H. Pylori and maintained on a PPI may be at risk for the 
development of atrophic gastritis.213However, the findings have not been confirmed in other 
studies.214 
Persons using NSAIDS or Aspirin 
EHSG suggests H. Pylori testing in patients who are naive NSAIDs users. A meta-analysis of 
five studies including 939 patients showed that H. Pylori eradication was associated with a 
reduced incidence of peptic ulcer in patients taking NSAIDs(OR 0.43, 95% CI 0.20-0.93). Sub-
analyses demonstrated that risk reduction was evident in NSAID-naive individuals, but not 
for those previously taking NSAIDs.215,219 
www.intechopen.com
 




EHSG recommends H. Pylori testing and eradication in patients with unexplained iron 
deficiency anaemia. There is emerging evidence to suggest that eradication of H. Pylori can 
improve iron deficiency anaemia216,217, but the available data do not prove cause and effect. 
Chronic ITP 
EHSG recommends H. Pylori testing and eradication in patients with chronic ITP. The 
available data support an association between H. Pylori infection and ITP.218 Studies have 
also shown that there is a significant increase in platelet count in patients with ITP after H. 
Pylori eradication.220,222,223,224  
Prevention of gastric cancer 
ACG recommends H. Pylori testing after endoscopic resection of early gastric cancer. EHSG 
recommends H. Pylori testing and eradication in first-degree relatives of patients with 
gastric cancer. Whether H. Pylori eradication reduces the risk of developing gastric cancer is 
unknown. H. Pylori eradication may protect against the progression of premalignant gastric 
lesions.225,226 H. Pylori eradication may decrease the risk of developing cancer in individuals 
without precancerous lesions from high risk populations.227 However, this may not apply to 
low-risk populations. 
7. Diagnostic tests for H. pylori infection  
Diagnostic tests for H. Pylori can be divided into endoscopic and non-endoscopic tests. 
Various diagnostic tests for H. Pylori infection are shown in Table 1-2. All the methods 
currently available for the detection of H. Pylori have their advantages and disadvantages 
regarding sensitivity, specificity, convenience, cost and immediacy. Choosing among these 
tests depends upon the clinical circumstance, the pre-test probability of infection, the 
accuracy of the tests, the availability and the relative costs. 
General recommendations from ACG  
When endoscopy is indicated, the test of first choice is the rapid urease test (RUT) in 
patients who have not been on a PPI within 1-2 week or an antibiotic or bismuth within 4 
week of endoscopy. 
For patients who have been taking a PPI, antibiotics or bismuth, it is appropriate to obtain 
biopsies from the gastric body and antrum for histology with or without RUT or plan testing 
with Urea breath test(UBT) or faecal antigen test(FAT) at a later date after withholding the 
offending agents for an appropriate period of time. 
Culture or PCR is not routinely recommended. 
UBTs and faecal antigen tests provide reliable means of identifying active H. Pylori infection 
before antibiotic therapy. 
In the setting of acute upper GI bleeding, a positive RUT indicates the presence of active H. 
Pylori infection, whereas a negative RUT and/or histology should be confirmed with 
another test. An antibody test provides a reasonably sensitive testing option. Alternatively, 
patient can undergo a UBT or FAT at a later date after withholding medications that can 
negatively affect the sensitivity of these tests for an appropriate period of time. 
Antibody testing for H. Pylori is appropriate in patients with uninvestigated dyspepsia in 
regions where the prevalence of H. Pylori infection is high. In low prevalence populations 
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(prevalence less than 20%), antibody tests should be avoided altogether or positive results 
should be confirmed with a test that identifies active infection, such as UBT or FAT prior to 






Non- Endoscopic   
1.Urea Breath Test 
 (13C & 14C) 
 Rapid, inexpensive and 
identifies active 
infection. 
 Excellent PPV 
regardless of H. Pylori 
prevalence. 
 Useful after H. Pylori 
therapy. 
 False negative results may 
be observed in patients who 
are taking PPIs, bismuth or 
antibiotics. 
 May not be available 
consistently. 
 
2.Serological Test or 
Antibody Test 
 
 Widely available. 
 Least expensive test. 
 Excellent NPV. 
 
 The PPV is greatly 
influenced by the 
prevalence of H. pylori 
infection. 
Not recommended for 
confirming eradication as 
positive results may reflect 
past rather than current 
infection. 
 
3. Fecal Antigen Test 
 
 Identifies active H. 
pylori infection. 
 High positive and 
negative predictive 
values. 
 Useful before and after 
H. Pylori treatment. 
 
 Collecting stool may be 
unpleasant to patients. 
 False negative results may 
be observed in patients who 
are taking PPIs, bismuth or 
antibiotics. 










 Rapid, inexpensive and 
accurate in properly 
selected patients. 
 False negative results may 
be observed in patients who 









 High sensitivity and 
specificity. 
 Expensive. 
 Requires trained personnel. 
3. Culture  Excellent specificity. 
 Allows determination of 
antibiotic sensitivities. 
 Sensitivity variable. 
 Requires infrastructure and 
trained personnel. 
 Expensive, time consuming, 
difficult to perform and not 
widely available. 
4. Polymerase Chain 
Reaction 
 High sensitivity and 
specificity. 
 Provides opportunity to 
test for antibiotic 
sensitivity. 
 False positive results may 
be due to contamination, 
homologous DNA 
sequences among various 
species, non-specific 
amplifications. 
 False negative results may 
be due to reaction failure. 
 Methodology not 
standardized across 
laboratories. 
 Not widely available. 
Table 1. 
 
Test Sensitivity Specificity 
Non-Endoscopic Tests    
1.Urea Breath Test 90%-96% 88%-98% 
2.Antibody Test 88%-94% 74%-88% 
3.Fecal Antigen Test 86%-96% 92%-97% 
Endoscopic Tests    
1.Rapid Urease Test 88%-95% 95%-100% 
2.Histology 93%-96% 98%-99% 
3.Culture 80%-98% 100% 
4.Polymerase Chain Reaction >95% >95% 
Table 2. 
Confirmation of eradication is indicated in any patients with an H. Pylori-associated ulcer, 
persistent dyspeptic symptoms despite the test-and-treat strategy, H. Pylori-associated 
MALT lymphoma and in individuals who have undergone resection of early gastric cancer. 
If testing to prove eradication were performed in the setting of endoscopy, histology or the 
combination of histology and RUT would be appropriate.  
UBT is the most reliable non-endoscopic test to document eradication of H. Pylori infection. 
The monoclonal FAT provides another non-endoscopic means of establishing H. Pylori cure. 
Testing to prove H. Pylori cure appears to be most accurate if performed at least 4 wk after 
the completion of antibiotic therapy.  
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7.1 Endoscopic diagnostic tests 
Currently available biopsy-based diagnostic methods for H. Pylori infection are the rapid 
urease test, histology, culture and polymerase chain reaction (PCR). 
7.1.1 Rapid Urease test (RUT) 
Rapid Urease tests depend on the activity of bacterial urease. Endoscopic biopsy specimens 
are placed into an agar gel or on a reaction strip containing urea, a buffering agent and a PH 
sensitive dye. If H. Pylori is present, its urease cleaves urea to liberate ammonia and 
bicarbonate, leading to an increase in the PH and change in the colour of the dye. CLO test, 
Hp Fast, HUT-test, Pyloritek and Pronto Dry are some of the commercially available RUT 
kits. The overall performance of these tests is comparable.228,229 
Although RUTs are rapid, inexpensive and easy to perform, their sensitivity is reduced 
under certain circumstances. The tests may produce a false negative result in patients with 
active or recent bleeding from the upper gastrointestinal tract when gastric contents are 
contaminated with blood.230,231,232 Furthermore, these tests may give a false negative result in 
patients who have recently been taking proton pump inhibitors (PPIs), H2-receptor 
antagonists (H2RAs), antibiotics, or bismuth containing compounds.228In these patients, the 
RUT is usually combined with other endoscopic or non-endoscopic tests to determine the 
presence or absence of the infection. It is also recommended to obtain biopsies from two 
sites, the body of the gastric angularis and greater curvature of the antrum.233 This may 
increase the sensitivity of the test. An alternative is to withhold the offending agents, such as 
PPIs or antibiotics for an appropriate period of time prior to endoscopy. The duration of the 
deleterious effects of medications on the sensitivity of the RUT is unknown. However, based 
on data from UBT, it is probably reasonable to withhold a PPI for 1-2 weeks and bismuth 
and antibiotics for four weeks prior to the RUT.234,235 
7.1.2 Histology 
Histological testing of gastric biopsy specimens is another method of diagnosing H. Pylori 
infection. A significant advantage of histology over other diagnostic tests is the ability to 
evaluate for pathological changes associated with H. Pylori infection, such as gastritis, 
atrophy, intestinal metaplasia and malignancy.236The presence of type B chronic gastritis 
(non-atrophic diffuse antral gastritis or atrophic pangastritis) may be used as a surrogate 
marker for the infection when organisms are not detected whereas the absence of chronic 
gastritis may be used as a marker for the absence of infection. However, the sensitivity of 
histology is affected by several factors, such as the site, number and size of gastric 
biopsies, method of staining, level of training of the examining pathologist and use of 
medications, such as bismuth, antibiotics and PPIs. It is therefore recommended to obtain 
a minimum of three biopsies, one from the greater curvature of the corpus, one from the 
greater curvature of the antrum and one from the angularis to maximize the diagnostic 
yield of histology.237 
7.1.3 Brush cytology 
Brush cytology may be used as an alternative to histology for the diagnosis of H. Pylori 
infection, especially in patients who have an increased risk of bleeding following forces 
biopsy. Data with endoscopic brush cytology are encouraging, with reported sensitivity and 
specificity of more than 95%.238 
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Bacterial culture is highly specific method for detecting active H. Pylori infection. In 
addition to identifying infection, it permits testing for sensitivity to anti-microbial agents.239 
However, bacterial culture is relatively insensitive240,241 and seldom performed in routine 
clinical practise. Not all hospital laboratories have necessary expertise or resources available 
to offer routine culturing. Furthermore, culturing H. Pylori is difficult, time consuming and 
expensive. 
Culture and sensitivity testing may be useful in patients with refractory disease since the 
incidence of resistance is very high in this subgroup. 
7.1.5 Polymerase chain reaction (PCR) 
Detection of H. Pylori by PCR is based on the amplification of a target DNA sequence in the 
bacterial genome. The use of PCR for the detection of H. Pylori from environmental samples 
is well documented.269,270 PCR can also be used to detect H. Pylori in biopsy 
specimens.261,262,265 In fact, PCR may be more sensitive than other biopsy-based diagnostic 
techniques in diagnosing H. Pylori infection.264,265 PCR testing may be more sensitive than 
other biopsy based tests in detecting H. Pylori infection in patients who are taking PPIs, H2 
RAs, antibiotics or bismuth containing compounds.263 The testing is also highly specific and 
allows testing for antibiotic sensitivities.266,267,268 
Although PCR has many advantages, its clinical use is limited due to its tendency towards 
false positive and false negative results. False positives can result from clinical or laboratory 
contamination, carry over contaminations and most importantly, similarities between the 
primer binding regions of H. Pylori and other organisms especially at the 3’ ends. False 
negatives can result from low number of target organisms, the presence of a specific PCR 
inhibitor, degenerated target DNA, and polymorphisms in the primer binding regions, 
especially at the 3’ ends, that prevent the amplification of the target DNA. Furthermore, the 
test is not widely available and the methodology is not standardized across laboratories. 
Newer PCR techniques, such as multiplex PCR assays may reduce false positive and false 
negative results and thereby improve the accuracy of the test. For example, TZAM HP 
multiplex PCR assay amplifies 10 DNA fragments from 5 DNA regions in the genome of H. 
Pylori at the same time. Amplifying more than one DNA region increases the sensitivity 
because the probability of amplifying several selected DNA regions is much higher than the 
chance of amplifying only one region. It also increases the specificity because probing 
different loci at the same time more accurately distinguishes one pathogen from another.265 
7.2 Non-endoscopic diagnostic tests 
Currently available non-endoscopic diagnostic tests for H. Pylori infection are urea breath 
test (UBT), antibody test and fecal antigen test (FAT). 
7.2.1 Urea breat test (UBT) 
The urea breath test, like the RUT, depends on the activity of bacterial urease. The test 
involves the ingestion of urea, labelled with either the non-radioactive isotope 13 C or the 
radioactive isotope 14 C, which is converted to labelled carbon dioxide by the bacterial 
urease. The labelled carbon dioxide can then be measured in expired air.242,243,244 Although 
the dose of radiation exposure in 14 C UBT is small, the 13 C UBT is preferred in children and 
women of child bearing potential.242,243  
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The UBT has excellent sensitivity and specificity242,243 therefore, it is considered to be the 
most reliable test to document H. Pylori infection. It can be used to screen for infection as 
well as to confirm eradication after H. Pylori treatment.244,245,246,247 However, UBTs may 
produce a false negative result in patients who are taking PPIs, bismuth or antibiotics. It is 
currently recommended to withhold bismuth and antibiotics for at least 28 days and a PPI 
for 7-14 days prior to UBT to reduce false negative results.234,235,248 It is unknown whether 
H2RAs affect the sensitivity of the UBT249, although these drugs are generally stopped for 
24-48 hours before the UBT. 
A urease blood test, using a 13 C- bicarbonate assay also reliably detects active H. Pylori 
infection before and after treatment. In the presence of H. Pylori, the ingestion of a 13 C- 
urea rich meal results in the production of labelled bicarbonate, which can be measured in 
serum.250,251 
7.2.2 Serological test or antibody test 
Antibody testing is based upon the detection of H. Pylori specific Ig G antibodies in serum, 
whole blood or urine. Antibodies to H. Pylori can be quantitatively assessed using 
laboratory-based ELISA and latex agglutination techniques or qualitatively assessed using 
office-based serological kits. 
Antibody testing is cheap, widely available and easy to perform. However, there are several 
factors limiting its usefulness in clinical practice. The test is less accurate when compared 
with other diagnostic tests.252 The test has high sensitivity (88-94%), but variable specificity 
(74-88%) with accuracy ranging from 83 to 98%. In general, office based serological kits are 
less accurate than laboratory-based quantitative tests. The PPV of the test is greatly 
influenced by the prevalence of H. Pylori infection.253 In a population with low prevalence 
of H. Pylori infection, a positive antibody test is more likely to be a false positive test. 
Finally, serological tests are unreliable indicators of H. pylori status in patients who have 
received treatment for the infection.254Although antibody titres fall in most patients after 
successful eradication, the rate and extent of the decline are highly variable and 
unpredictable. 
7.2.3 Fecal antigen test (FAT) 
H. pylori infection can be diagnosed by identifying H. Pylori specific antigens in the stool by 
enzyme immunoassay with the use of polyclonal or monoclonal anti-H. Pylori 
antibodies.255,256 The FAT is a reliable test to diagnose H. Pylori infection as well as to 
confirm eradication after treatment and can be used interchangeably with the UBT. Both 
polyclonal and monoclonal tests have excellent sensitivity, specificity, positive and negative 
predictive values for diagnosing infection before treatment.255 However, in the post-
treatment setting, only the monoclonal test appears to have sensitivity, specificity and 
predictive values of greater than 90%. The polyclonal test appears to have less satisfactory 
sensitivity and positive predictive value.255 Therefore, in the post-treatment setting, the 
monoclonal FAT is more reliable than the polyclonal test. The FAT may be effective in 
confirming eradication as early as 14 days after treatment257 but, the general 
recommendation is to perform the test more than 4 weeks after treatment.255 
The FAT has its own disadvantages. Like the UBT, the FAT may produce a false negative 
result in patients who are taking PPIs, antibiotics or bismuth.258,259 To reduce false negative 
results, it is generally recommended to withhold bismuth and antibiotics for at least 4 weeks 
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and a PPI for 2 weeks prior to the FAT. The FAT may produce a false positive result in 
patients with acute upper gastrointestinal bleeding.231,260 This may be due to cross-reactivity 
with blood products. Furthermore, the process of stool collection may be unpleasant to 
patients. 
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disease, epidemiology, pathophysiology, molecular-cellular mechanisms, clinical care, and alternative
medicine. Each chapter provides a unique view. The book is not only for professionals, but also suitable for
regular readers at all levels.
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